Our expert for hiPSC-derived cardiac cells, as well as cell-based assays & services for drug safety and efficacy screenings
Human iPSC-derived cardiomyocytes combined with the xCELLigence® RTCA CardioECR system enables detailed detection of potential cardioactive and proarrhythmic effects of test compounds on the contractility and electrophysiology. This combination provides a highly relevant in vitro assay to study the cardiac safety profile of compounds during drug development.
You can find a step-by-step description on how to combine our hiPSC-derived cardiomyocytes with the xCELLigence® RTCA CardioECR system with for impedance and electrophysiology measurements in the following User Guides:
The xCELLigence® RTCA CardioECR system records cellular impedance (presented as Cell Index (CI)) and electrical field potential (presented as extracellular recording (ECR)) of hiPSC-derived cardiomyocytes in parallel, using proprietary microelectrode array (MEA) technology. A typical CI trace (top panel) and ECR trace (bottom panel) of a Pluricyte® Cardiomyocyte monolayer is shown here.
Case studies were performed to assess the effects of cardioactive compounds on the electrophysiology (presented as extracellular recording (ECR)) and cellular impedance (presented as Cell Index (CI)) of Pluricyte® Cardiomyocytes using the xCELLigence® RTCA CardioECR system. Pluricyte® Cardiomyocytes show the expected pharmacological responses to reference compounds in a reproducible manner. Below, an example is shown of the effect of the reference compound, isoproterenol.
Pluricyte® Cardiomyocytes show a positive chronotropic and inotropic response to isoproterenol
Isoproterenol activates the β-adrenergic receptor, which results in an increased beat rate (left panel). The impedance signal can be used to assess compound effects on cell contractility. Isoproterenol caused an increase in impedance peak amplitude in Pluricyte® Cardiomyocytes (right panel), indicating a positive inotropic effect of isoproterenol.